You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Request a contact

Stay informed

Live Chat

The 2DR Era

Explore dolutegravir based, 2-drug regimens for your diverse patient needs.

Dovato tile
Learn More | Juluca
Image of pill may not reflect the actual size.
Times are changing | 2DR Era

2DR: Meeting a clinical need

The HIV treatment landscape has changed dramatically over the past 30 years, with each decade serving as a foundation for the next to build upon. Today marks the beginning of the next era in HIV therapy...THE 2DR ERA. 1

  • A 20-year-old starting a 3-drug regimen may be on therapy for nearly 6 DECADES, which translates to MORE THAN 60,000 DOSES of individual medications 4
Timeline of HIV Treatment

References:

  1. A timeline of HIV/AIDS. https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline/. Accessed July 2023
  2. Llibre JM, et al. J Antimicrob Chemother. 2016;71:856-861.
  3. Antiretroviral drugs used in the treatment of HIV infection. https://www.fda.gov/. Accessed November 2021
  4. The Antiretroviral Therapy Cohort Collaboration. Lancet HIV. 2017;4:e349-e356.
  5. Juluca Summary of Product Characteristics. Available from: https://www.medicines.ie/medicines/juluca-50-mg-25-mg-film-coated-tablets-34548/, last accessed July 2023
  6. Dovato Summary of Product Characteristics. Available from: https://www.medicines.ie/medicines/dovato-50-mg-300-mg-film-coated-tablets-34871/spc last accessed July 2023
  7. ViiV Healthcare. V&R Marketing Authorisation in Europe. Available at: https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2020/december/viiv-healthcare-announces-the-marketing-authorisation/
  8. VOCABRIA Suspension for Injection Summary of Product Characteristics. Available at: https://www.medicines.ie/medicines/vocabria-600-mg-prolonged-release-suspension-for-injection-35220/spc#tabs Last accessed: September 2023
  9. REKAMBYS Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/rekambys-epar-product-information_en.pdf Last accessed: September 2023
  10. EACS guidelines Version 11.0, Oct 2021. Available at: https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf Last accessed: September 2023
  11. DHHS Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents living with HIV. Jan 2022. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines Last accessed: September 2023
  12. Saag MS, et al. JAMA 2020;324:1651–69

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.